Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 19:02:26 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Calliditas and our update ahead of H2 2023

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Calliditas and our update ahead of H2 2023

2023-08-18 08:25:00

In Q2 Calliditas regains the sequential sales growth but the conversion from patient enrollment into prescriptions and sales remains a challenge even if it is improving. Our take is that it is this conversion that is the main reason for a reduced 2023 product sales guide. Calliditas reduces the mid-point guide by 18-19%. Our updated view is a base case valuation of SEK 295 (310) and a Bull Case of SEK 445 (485) and a Bear Case of SEK 75 (85).

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/